Mineralys Therapeutics Inc

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mineralys Therapeutics advances in cardio renal disorders amid financial strength

Mineralys Therapeutics is strategically positioned to address aldosterone-driven cardio renal disorders with a strong focus on hypertension and chronic kidney disease.
While the company boasts a robust financial position and progress in clinical trials, challenges such as therapeutic outcomes and regulatory requirements need to be carefully navigated.
Amidst uncertainties and risks, Mineralys Therapeutics has opportunities to expand its product portfolio, explore strategic partnerships, and address unmet medical needs in the cardio renal space.

Mineralys Therapeutics reports positive trial results amidst financial challenges

Mineralys Therapeutics shows promise with positive trial results and a strong cash position, but faces challenges with revised trial timelines and financial losses.
The company's focus on expanding its drug pipeline and governance structure presents opportunities for future growth and market penetration.
Navigating patient enrollment, market potential assessment, and cost management will be crucial for Mineralys to capitalize on its strengths and opportunities.

Mineralys Therapeutics advances hypertension treatment with promising trials and financial insights

Mineralys Therapeutics is making significant progress in developing lorundrostat for hypertension treatment.
Despite challenges in trials and financial pressures, the company remains optimistic and committed to advancing its programs.
Analyst questions and discussions during the earnings call reflect a comprehensive approach to addressing key industry topics.

Mineralys Therapeutics Inc reports Q1 loss, progresses in hypertension trials

Mineralys Therapeutics Inc faces financial challenges with increased expenses but shows strength in clinical trial progress and targeted treatment approaches. Opportunities lie in expanding drug benefits and preventing kidney damage through effective hypertension treatment.

Mineralys Therapeutics progresses key trials amidst financial challenges in Q2

Mineralys Therapeutics is advancing its lead asset lorundrostat for hypertension with key trials progressing as planned.
Financially, the company remains well-capitalized but faces challenges with increased R&D expenses impacting net loss.
Management's confidence in program progress and upcoming milestones signals a positive outlook for the company's future.

Mineralys Therapeutics advances lorundrostat trials amidst financial strength

Mineralys Therapeutics is making notable progress in clinical development, supported by a solid financial position. While facing challenges in trial endpoints and safety concerns, the company has opportunities to capitalize on positive trial outcomes and address investor inquiries effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, announced today that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology's 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

RADNOR, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the closing of its initial public offering of 13,800,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $220.8 million. Mineralys' common stock is listed on the Nasdaq Global Select Market under the ticker symbol “MLYS.”

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.

There's a Lot to Love About Mineralys' Valentine's Day IPO

RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Mineralys. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $192.0 million. Shares of Mineralys common stock are expected to begin trading on the Nasdaq Global Select Market on February 10, 2023 under the ticker symbol “MLYS.” The offering is expected to close on February 14, 2023, subject to the satisfaction of customary closing conditions. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

Mineralys Therapeutics Inc. MLYS, has set terms for its initial public offering, in which the Pennsylvania-based hypertension treatment company looks to raise up to $160 million. the company is offering 10 million shares in the IPO, which is expected to price between $14 and $16 a share.

Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million

A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market.

Hypertension Drug Maker Mineralys Therapeutics Prepares for $100 million IPO

Mineralys Therapeutics has filed to raise drug candidate development funding via a U.S. IPO. The firm is developing treatments for hypertension and chronic kidney disease.

Mineralys Therapeutics Builds On Phase 2 Trial Success With IPO Filing

News for Mineralys Therapeutics Inc Stock (MLYS)